Cargando…

Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor

The dopamine D2/D3 receptor (D(2)R/D(3)R) agonists are used as therapeutics for Parkinson’s disease (PD) and other motor disorders. Selective targeting of D(3)R over D(2)R is attractive because of D(3)R’s restricted tissue distribution with potentially fewer side-effects and its putative neuroprotec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adhikari, Pramisha, Xie, Bing, Semeano, Ana, Bonifazi, Alessandro, Battiti, Francisco O., Newman, Amy H., Yano, Hideaki, Shi, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069330/ https://www.ncbi.nlm.nih.gov/pubmed/33924613 http://dx.doi.org/10.3390/biom11040570

Ejemplares similares

Scaffold Hybridization Strategy Leads to the Discovery of Dopamine D(3) Receptor-Selective or Multitarget Bitopic Ligands Potentially Useful for Central Nervous System Disorders
por: Bonifazi, Alessandro, et al.
Publicado: (2021)

Correction: Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D(3) receptor agonists
por: Cao, Yongkai, et al.
Publicado: (2018)

Novel and Potent Dopamine D(2) Receptor Go-Protein Biased Agonists
por: Bonifazi, Alessandro, et al.
Publicado: (2019)

Bitopic ligands: all-in-one orthosteric and allosteric
por: Kamal, Maud, et al.
Publicado: (2009)

Highly Potent and Selective Dopamine D(4) Receptor Antagonists Potentially Useful for the Treatment of Glioblastoma
por: Pavletić, Pegi, et al.
Publicado: (2022)

Bitopic Binding Mode of an M(1) Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes
por: Bradley, Sophie J., et al.
Publicado: (2018)

Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB(2) Receptor
por: Morales, Paula, et al.
Publicado: (2020)

Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism
por: Lane, J Robert, et al.
Publicado: (2020)

Publicity and reports of behavioral addictions associated with dopamine agonists
por: Gendreau, Katherine E., et al.
Publicado: (2016)

The effect of two selective A(1)‐receptor agonists and the bitopic ligand VCP746 on heart rate and regional vascular conductance in conscious rats
por: Cooper, Samantha L., et al.
Publicado: (2020)

Synthesis of New Bitopic Tetra(pyrazolyl)-Ligands with Neopentane and O-Xylene Backbones
por: Potapov, Andrei S., et al.
Publicado: (2012)

The Role of Orthosteric Building Blocks of Bitopic Ligands for Muscarinic M1 Receptors
por: Volpato, Daniela, et al.
Publicado: (2020)

New Insights into Bitopic Orthosteric/Allosteric Ligands of Cannabinoid Receptor Type 2
por: Ferrisi, Rebecca, et al.
Publicado: (2023)

Biased, Bitopic, Opioid–Adrenergic Tethered Compounds May Improve Specificity, Lower Dosage and Enhance Agonist or Antagonist Function with Reduced Risk of Tolerance and Addiction
por: Root-Bernstein, Robert
Publicado: (2022)

Allosteric Antagonism of the A(2A) Adenosine Receptor by a Series of Bitopic Ligands
por: Gao, Zhan-Guo, et al.
Publicado: (2020)

Orthosteric and Allosteric Dual Targeting of the Nuclear Receptor RORγt with a Bitopic Ligand
por: Meijer, Femke A., et al.
Publicado: (2021)

Dopamine D(4) Receptor-Selective Compounds Reveal Structure–Activity Relationships that Engender Agonist Efficacy
por: Keck, Thomas M., et al.
Publicado: (2019)

In Search of Synergistic Insect Repellents: Modeling of Muscarinic GPCR Interactions with Classical and Bitopic Photoactive Ligands
por: Niklas, Beata, et al.
Publicado: (2022)

Design and Synthesis of Conformationally Flexible Scaffold as Bitopic Ligands for Potent D(3)-Selective Antagonists
por: Kim, Ho Young, et al.
Publicado: (2022)

Novel Xanomeline-Containing Bitopic Ligands of Muscarinic Acetylcholine Receptors: Design, Synthesis and FRET Investigation
por: Matera, Carlo, et al.
Publicado: (2023)

Complex k-uniform tilings by a simple bitopic precursor self-assembled on Ag(001) surface
por: Kormoš, Lukáš, et al.
Publicado: (2020)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Dopamine Agonists and Pathologic Behaviors
por: Kelley, Brendan J., et al.
Publicado: (2012)

Dopamine Agonists for Pituitary Adenomas
por: Cooper, Odelia, et al.
Publicado: (2018)

Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody
por: Hinke, Simon A., et al.
Publicado: (2018)

Induction of Polyacetylene to a Chiral Smectic Liquid Crystal–Chiral Direct Conversion
por: Yatsu, Akiko, et al.
Publicado: (2020)

Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology
por: Borovac, Josip Anđelo
Publicado: (2016)

Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands
por: Gado, Francesca, et al.
Publicado: (2022)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

Impulse control disorders and dopamine agonists
por: Martins, D., et al.
Publicado: (2021)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022)

The effects of dopamine and dopamine receptor agonists on the phototransduction cascade of frog rods
por: Nikolaeva, Darya A., et al.
Publicado: (2019)

Tropane-Based Ibogaine Analog Rescues Folding-Deficient Serotonin and Dopamine Transporters
por: Bhat, Shreyas, et al.
Publicado: (2020)

Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
por: Costa, M.L., et al.
Publicado: (2022)

Pathological gambling and dopamine agonists: A phenotype?
por: Pinder, Roger M
Publicado: (2007)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

Non-ergot dopamine agonists and heart failure
por: Şener, Yusuf Ziya, et al.
Publicado: (2019)

Predictors of dopamine agonist resistance in prolactinoma patients
por: Vermeulen, Elle, et al.
Publicado: (2020)

Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D(2)/D(3) Receptor Agonist Selectivity
por: Zou, Mu-Fa, et al.
Publicado: (2016)

Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists
por: Pogorelov, Vladimir M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8g1in68g77idn7vvvhrpog2jk9